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Abstract: Objectives Soft tissue sarcoma (STS) is a rare malignancy with a 5 year overall
survival rate of 55%. Neoadjuvant radiotherapy is commonly used in preparation for
surgery, but methods to assess early response are lacking despite pathological
response at surgery being predictive of overall survival, local recurrence and distant
metastasis. Multiparametric MR imaging (mpMRI) is used to assess response in a
variety of tumours but lacks a robust, standardised method. The overall aim of this
study was to develop a feasible imaging protocol to identify imaging biomarkers for
further investigation. Methods Fifteen patients with biopsy-confirmed STS suitable for
preoperative radiotherapy and radical surgery were imaged throughout treatment. The
mpMRI protocol included anatomical, diffusion weighted and dynamic contrast-
enhanced imaging, giving estimates of apparent diffusion coefficient (ADC) and the
area under the enhancement curve at 60 s (iAUC 60 ). Histological analysis of
resected tumours included detection of CD31, Ki67, HIF and calculation of a hypoxia
score. Results There was a significant reduction in T1 at visit 2 and in ADC at visit 3.
Significant associations were found between hypoxia and pre-treatment iAUC 60 , pre-
treatment ADC and mid-treatment iAUC 60 . There was also statistically significant
Powered by Editorial Manager® and ProduXion Manager® from Aries Systems Corporation
association between mid-treatment ADC and Ki67. Conclusions This work showed that
mpMRI throughout treatment is feasible in patients with STS having neoadjuvant
radiotherapy. The relationships between imaging parameters, tissue biomarkers and
clinical outcomes warrant further investigation. Advances in Knowledge mpMRI based
biomarkers have good correlation with STS tumour biology and are potentially of use
for evaluation of radiotherapy response.
Powered by Editorial Manager® and ProduXion Manager® from Aries Systems Corporation
Response to Reviewer 2 
1- Missing Data 
The expected sample size was 15 patients and the available data was less than that. If the 
study considered completed, is it safe to use missing data?  If the collected data was enough 
for the authors before reaching 15 patients, do we consider this result as a 
preliminary/interim result? Is the interim analysis planned?  Does that mention in the 
protocol?  If not, the authors should include them as an amendment. 
 
The study design was for a sample size of 15 patients, which was felt to be adequate to 
assess the feasibility of applying this protocol in this patient group.  We are not planning to 
enrol any additional patients and we consider the study to be complete.  Our apologies, we 
are unsure exactly what the reviewer means by ‘is it safe to use missing data?’.  We included 
all the collected data in our analysis and we believe that this is appropriate for detecting 
groupwise changes.  We have added a line in the results section to emphasise this: 
 
Briefly, by the close of the study 15 patients were recruited and twelve scanned (nine had 
three scans, three had only the first two).  All collected data were included in our analysis. 
 
I found reluctancy in presentations of results in the discussion part, such as the following 
statements: 
i). Incomplete datasets were due to incorrect protocols being used, rather than poor patient 
compliance 
ii) Postradiotherapy the correlation was not significant, but there were only ten observations 
at this stage. 
 
We have reworded the first point as: 
i) The imaging protocol is deliverable as shown by the good patient compliance, 
and there are some interesting findings 
Point 2 was removed. 
 
2- The discussion part was very short. 
My suggestion to correlate positive findings (such as iAUC60 and hypoxia score and mid-
treatment ADCand Ki67) in this study for specific histopathology, soft tissue sarcoma, with 
different tumors, in clinical and Preclinical settings of other studies. 
 
Many thanks for this suggestion.  We have added the following text and references to the 
discussion: 
 
AUC inversely correlated with hypoxia score 
This is consistent with previous work in a mouse xenograft model, which showed reduced 
AUC in hypoxic tumour regions defined by pimonidazole staining29 
 
Mid-Tx ADC inversely correlated with Ki67 at resection 
The relationship between ADC and Ki67 has been explored previously, and reported in a 
meta-analysis that confirmed this negative correlation in many tumour types.   
 
No CAIX at surgery have higher ADC mid Tx 
Itemised List of Revisions
In a previous study in melanoma xenografts, ADC was shown to be inversely related to 
hypoxic fraction determined by pimonidazole staining31.  The relationship between CAIX and 
ADC has been explored previously but no relationship was found32, possibly because (unlike 
pimonidazole staining) CAIX is a downstream marker of hypoxia, influenced by other factors. 
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Soft tissue sarcoma (STS) is a rare malignancy with a 5 year overall survival rate of 55%.  Neoadjuvant 
radiotherapy is commonly used in preparation for surgery, but methods to assess early response 
are lacking despite pathological response at surgery being predictive of overall survival, local 
recurrence and distant metastasis.  Multiparametric MR imaging (mpMRI) is used to assess response 
in a variety of tumours but lacks a robust, standardised method.  The overall aim of this study was 
to develop a feasible imaging protocol to identify imaging biomarkers for further investigation. 
Methods 
Fifteen patients with biopsy-confirmed STS suitable for preoperative radiotherapy and radical 
surgery were imaged throughout treatment.  The mpMRI protocol included anatomical, diffusion 
weighted and dynamic contrast-enhanced imaging, giving estimates of apparent diffusion 
coefficient (ADC) and the area under the enhancement curve at 60 s (iAUC60).  Histological analysis 
of resected tumours included detection of CD31, Ki67, HIF and calculation of a hypoxia score. 
Results 
There was a significant reduction in T1 at visit 2 and in ADC at visit 3.  Significant associations were 
found between hypoxia and pre-treatment iAUC60, pre-treatment ADC and mid-treatment iAUC60. 
There was also statistically significant association between mid-treatment ADC and Ki67.   
Conclusions 
This work showed that mpMRI throughout treatment is feasible in patients with STS having 
neoadjuvant radiotherapy.  The relationships between imaging parameters, tissue biomarkers and 
clinical outcomes warrant further investigation. 
Advances in Knowledge 
mpMRI based biomarkers have good correlation with STS tumour biology and are potentially of 
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Soft tissue sarcoma (STS) is a rare malignancy with a 5 year overall survival rate of 55%.  
Neoadjuvant radiotherapy is commonly used in preparation for surgery, but methods to 
assess early response are lacking despite pathological response at surgery being predictive 
of overall survival, local recurrence and distant metastasis.  Multiparametric MR imaging 
(mpMRI) is used to assess response in a variety of tumours but lacks a robust, standardised 
method.  The overall aim of this study was to develop a feasible imaging protocol to identify 
imaging biomarkers for further investigation. 
Methods 
Fifteen patients with biopsy-confirmed STS suitable for preoperative radiotherapy and 
radical surgery were imaged throughout treatment.  The mpMRI protocol included 
anatomical, diffusion weighted and dynamic contrast-enhanced imaging, giving estimates 
of apparent diffusion coefficient (ADC) and the area under the enhancement curve at 60 s 
(iAUC60).  Histological analysis of resected tumours included detection of CD31, Ki67, HIF 
and calculation of a hypoxia score. 
Results 
There was a significant reduction in T1 at visit 2 and in ADC at visit 3.  Significant 
associations were found between hypoxia and pre-treatment iAUC60, pre-treatment ADC 
and mid-treatment iAUC60. There was also statistically significant association between mid-
treatment ADC and Ki67.   
Conclusions 
This work showed that mpMRI throughout treatment is feasible in patients with STS having 
neoadjuvant radiotherapy.  The relationships between imaging parameters, tissue 
biomarkers and clinical outcomes warrant further investigation. 


































































mpMRI based biomarkers have good correlation with STS tumour biology and are 





































































Soft tissue sarcoma (STS) is a rare and heterogeneous malignancy. There were 3298 new 
diagnoses in the UK in 2010, and the 5-year overall survival rate was 55%1.  Tumour grade 
is prognostic, with 5-year metastasis-free survival rates of 71% and 44% for intermediate 
and high grade tumours respectively2.  Surgery, the main treatment for STS of the limb and 
trunk, involves excising the lesion along with a tumour-free margin of around 1-2 cm, 
subject to anatomical constraints.  In intermediate/high grade tumours or those which 
require extensive surgery, this is often not possible without risk to function.  In these 
situations, radiotherapy is employed either pre- or post-operatively.  Post-operative 
radiotherapy requires a higher dose being delivered to a larger volume but can be reserved 
for situations where an inadequate margin is obtained. Pre-operative radiotherapy may be 
used to shrink a tumour, for some subtypes3 making a tumour more operable4, or to sterilise 
the margins in preparation for excision5.  The use of a lower dose and reduction in the 
irradiated volume for pre-operative compared to post-operative radiotherapy results in 
similar local control, but with a reduction in late toxicity and better function6. There is no 
consensus on the optimal approach for radiotherapy in STS, with a rationale for both pre 
and post-surgical radiotherapy. 
 
There is currently no method to assess early response to pre-operative radiotherapy, despite 
pathological response at surgery being predictive of overall survival, local recurrence7 and 
distant metastasis8,9.  Imaging biomarkers are attractive because they are non-invasive, and 
MR is available in most centres. Volume change in STS during pre-operative radiotherapy 
is minimal despite marked pathological response3, and tumour size changes (RECIST criteria 
and/or three-dimensional tumour volumes) are poor predictors of tumour-free surgical 



































































Multiparametric MR imaging (mpMRI) has been used to demonstrate radiotherapy response 
early in treatment, which might allow prompt progression to definitive treatment in poorly-
responding tumours11–13. Conversely, some STS such as myxoid liposarcoma may respond 
adequately with lower doses of radiotherapy reducing late effects without compromising 
outcome14.  Use of functional measures such as dynamic contrast-enhanced (DCE) MRI 
(measuring tissue microvasculature), and diffusion-weighted imaging (DWI) (measuring 
restriction of water molecule diffusion) has been shown to increase the ability of imaging 
to reflect the amount of tumour necrosis15–18, but protocols varied widely and image analysis 
often required careful selection of tumour subregions.  Delivery of a robust protocol suitable  
for large multicentre studies is challenging.  This study aligns with domain I of the imaging 
biomarker road map19, assessing the feasibility of delivering a robust protocol across 
different anatomical sites, but within a single institute. 
 
The overall aim of this study was to identify imaging parameters suitable for investigation 
as prognostic factors in a larger study.  The specific aims were to (i) develop a well-tolerated 
imaging protocol allowing for repeat scanning, (ii) identify imaging parameters that change 
significantly during radiotherapy, and (iii) determine relationships between imaging 
parameters and histological features in resected tumour tissue.  As part of this exploratory 
assessment, particular attention was focussed on post-surgical hypoxic regions in the 
resected tumour, a parameter known to affect survival20,21. 
Materials and Methods 
Patients 
In this prospective study, fifteen patients with biopsy-confirmed intermediate or high-grade 
STS suitable for preoperative radiotherapy (50 Gy in 25 fractions) and radical surgery were 
recruited.  This study had a favourable ethical opinion (13/NW/0500) and all patients gave 



































































Patients underwent MRI before radiotherapy (within 4 weeks of the start of treatment), in 
week 2 or 3 of radiotherapy, and 2-4 weeks after radiotherapy.  Within one month of the 
post-radiotherapy visit, the tumours were surgically resected.  At surgery, proximal, distal, 
medial, lateral, depth and superficial margins were demarcated.  
Imaging protocol 
Patients were imaged at 1.5 T (Siemens Magnetom Avanto, Siemens Healthineers, Erlangen, 
Germany) using either the peripheral or body matrix coil with the appropriate elements of 
the spine array.  Imaging began with standard clinical sequences (pre-contrast transverse 
and coronal T1w and T2w, post-contrast transverse and coronal T1w with fat saturation, all 
turbo spin-echo) and continued with trial sequences as shown in table 2.  During the 
dynamic sequence, 0.1 ml/kg Gadovist was injected using a power injector at 2 ml/s, 
followed by 20 ml saline at the same rate.   
Image Analysis 
ADC maps were calculated at the time of acquisition.  Images were analysed using Python 
(Version 3.6).  T1 maps were calculated by fitting the saturation recovery turbo FLASH 
equation on a pixel-by-pixel basis22.  The integrated area under the curve in the first 60 
seconds after injection (iAUC60) was calculated on a pixel-by-pixel basis using trapezoidal 
integration, after converting the signal intensity vs time curves to contrast agent 
concentration vs time curves23.  
 
Tumours were outlined on T2w images by BS (confirmed by a consultant radiologist with 
expertise in MRI), and volumes automatically calculated from the known voxel size.  These 
regions of interest (ROIs) were transferred to the dynamic images by nearest-neighbour 
interpolation and to the ADC maps by referring to anatomical landmarks to ensure that the 


































































plane by one pixel to avoid partial volume effects at the region edges.  The median and 
interquartile range over the whole tumour ROI was calculated for ADC, iAUC60 and T1. 
 
Histological Analysis of Resected Tumours 
Immunohistochemistry was performed on 4 µm sections from formalin-fixed paraffin-
embedded (FFPE) tumour resection samples to score hypoxia inducible factor – 1 alpha 
(HIF-1α), carbonic anhydrase IX (CAIX), antigen KI-67 (Ki67) and CD31. HIF-1α, CAIX and 
Ki67 staining was performed using the Bond-Max Automated staining system (Leica 
Biosystems, Milton Keynes, UK). Slides were de-waxed and rehydrated and antigen retrieval 
was carried out at pH 9.0 for 40 min at 100°C. The primary antibodies were HIF-1a (BD 
Biosciences 610959; 1:100 dilution), CAIX (NCL-L-CAIX, Novascastra, Leica Biosystems; 1:100 
dilution), Ki67 (clone MIB-1, Dako M7240; 1:100 dilution), and CD31 (M0823 Dako; 1:50 
dilution). For HIF-1α, Ki67 and CD31 the negative control was mouse IgG1 (Dako X0931) 
and for CAIX was mouse IgG2a (Dako, Ely, UK, X0943). All dilutions were in antibody diluent 
(Leica AR9352) and negative controls were diluted to the same protein concentration as the 
primary.  Slides were stained using a standard BOND processing protocol (available on 
request) and Bond Polymer Refine Detection System (Leica DS9800). Colorectal cancer cell 
line spheroids with a diameter <500 m were used as a positive control for HIF-1α and 
CAIX. A FFPE biopsy of normal human placenta was used as a positive control for CD31. 
 
The percentage of tumour cells per core expressing membranous CAIX was scored by a 
sarcoma pathologist (PS) at ×8 magnification with negative controls available for 
comparison. Other markers were scored using automated image analysis (Definiens tissue 
studio v.4.2; Definiens, Munich, Germany). 
 
The percentage of tumour material was assessed by a sarcoma pathologist (PS) on a 


































































RNA/DNA Purification Plus Kit (Norgen, Thorold, Ontario, Canada) including DNase I 
treatment. The High-Capacity cDNA Reverse Transcription Kit (Life Technologies, Paisley, 
UK) was used to reverse transcribe total RNA.  cDNA was preamplified using a custom pool 
of TaqMan assays (Life Technologies) and TaqMan PreAmp Master Mix (Life Technologies). 
 
Expression of a 24-gene hypoxia signature derived for STS24 and two endogenous control 
genes selected for STS25 was determined using custom 384-well TaqMan array cards (Life 
Technologies) on a QuantStudio 12K Flex Real-Time PCR System (Life Technologies) using 
TaqMan Fast Advanced Master Mix (Life Technologies) according to the manufacturer’s 
guidelines.  The geometric mean of the endogenous control genes was used for 
normalisation.  Hypoxia scores (HS) were calculated as the normalised median expression 
of the 24 hypoxia genes (note that the median is used due to the small sample size in this 
study, rather than the method presented previously24). 
 
Statistical Analysis 
In this small feasibility study, changes in median T1, ADC and iAUC60 between the three 
visits were assessed using a Wilcoxon signed ranks test.  Correlations between imaging and 
histology parameters were assessed by calculating the Pearson correlation coefficient and 
its associated p-value using the t distribution.  Differences in imaging parameters between 
the tumours with and without CAIX staining was assessed using the Mann-Whitney U test.  
No correction was made for multiple comparisons. 
Results 
Patients 
Figure 1 shows a flow diagram for enrolment, imaging and analysis.  Briefly, by the close of 
the study 15 patients were recruited and twelve scanned (nine had three scans, three had 
only the first two).  All collected data were included in our analysis.  As of January 2019, 



































































one patient had died from acute myeloid leukaemia and two had developed metastatic 
disease (one patient had a lung metastasis resected and the other developed a solitary 
spinal metastasis).  
 
Image Analysis 
No significant reduction in volume was observed across visits.  The median volumes with 
their interquartile ranges in cm3 were: 29 (22-51) for visit 1, 34 (23-48) for visit 2 and 25 
(10-32) for visit 3.  In comparison with pre-radiotherapy values, there was a significant 
reduction in T1 at visit 2 (p=0.008) (Figure 2) and in ADC at visit 3 (p=0.04), with example 
ADC maps shown in Fig 3 for two patients.  No significant changes in iAUC60 were seen 
over the three visits. 
 
Histological results 
Pearson correlation coefficients between imaging and histological parameters are shown 
with their p-values in Table 3.  Significant correlations were found between hypoxia scores 
and pre-treatment iAUC60 (r = -0.64, p = 0.03), pre-treatment ADC (r = 0.63, p = 0.03) and 
mid-treatment iAUC60 (r = -0.63, p = 0.03). There was also a significant correlation between 
mid-treatment ADC and Ki67 (r = -0.66, p=0.02).  Stratification of patients by CAIX staining 
demonstrated significant differences in T1 (visit 1 p = 0.003, visit 2 p = 0.01, visit 3 p = 
0.03), and iAUC60 at visit 1 (p = 0.03). 
Discussion 
In this work we developed a mpMRI protocol for STS, including established functional and 
structural imaging, that was acceptable for patients and that could be applied several times 
during radiotherapy.  The imaging protocol is deliverable as shown by the good patient 



































































reported the use of mpMRI in STS in neoadjuvant radiotherapy with a time point early in 
treatment.. 
 
We applied the techniques of DCE-MRI, DWI and T1 measurement to explore radiotherapy-
related changes to tumour tissue not reflected by changes in size.  As found in several 
previous publications3,4,10, size change varied between tumours and was not related to any 
histological parameters measured at surgery.  Since conventional RECIST criteria cannot be 
associated with radiotherapy response, a non-invasive imaging biomarker predictive of 
overall survival, local control7 and distant metastasis8,9 is desirable and could be used to 
stratify patients for treatment intensification or de-intensification.  The tissue T1 decreased 
significantly between baseline and mid-treatment but by the end of radiotherapy the main 
variation in T1 was between patients.  T1 changes can reflect a wide range of alterations in 
tissue structure26 resulting in large variations in values between patients, which complicates 
interpretation of tumour revascularisation between baseline and early treatment.  Tumours 
with positive staining for CAIX had a significantly shorter T1 at all three visits, consistent 
with the expected T1 shortening effect of deoxyhaemoglobin.  ADC increased significantly 
between baseline and post-treatment, as shown in previous work27 and is hypothesised to 
reflect decreased cellularity and increased necrosis28.  Pre-treatment ADC values were similar 
to those reported in previous studies27,28 though, as noted by other authors, the range of 
baseline values was large. 
 
There was an inverse correlation between iAUC60 and hypoxia score.  iAUC60 is a semi-
quantitative parameter with no direct physiological interpretation.  A source of the negative 
correlation observed both at baseline and early in treatment could be poor tumour 
perfusion resulting in a lower iAUC60 and the post treatment hypoxia observed.  This is 
consistent with previous work in a mouse xenograft model, which showed reduced AUC in 


































































positive staining for post-treatment CAIX had significantly higher iAUC60, which is not 
consistent with the expected relationship between iAUC60, perfusion and oxygenation.  The 
inverse correlation between mid-treatment ADC and Ki67 at resection suggests that tumours 
with a good initial response to radiotherapy (lower cell density, higher ADC) subsequently 
have less proliferation at resection.  The relationship between ADC and Ki67 has been 
explored previously, and reported in a meta-analysis that confirmed this negative correlation 
in many tumour types30.  Similarly, tumours that show no staining for CAIX at resection 
(normoxic at surgery) have a significantly higher ADC early in treatment (lower cell density).  
In a previous study in melanoma xenografts, ADC was shown to be inversely related to 
hypoxic fraction determined by pimonidazole staining31.  The relationship between CAIX 
and ADC has been explored previously but no relationship was found32, possibly because 
CAIX is a downstream marker of hypoxia which can be regulated by other factors whereas 
pimonidazole represents a more direct measure.  Correlation between pre-treatment ADC 
and hypoxia score is more difficult to interpret as ADC is measured long before the resection 
of the tumour. 
 
This study has several limitations.  The number of patients was small, prohibiting 
examination of differences between responders and non-responders.  The results should be 
interpreted with caution due to sample size and differences in measurement timepoint, but 
the main aim of the study was to develop a suitable imaging protocol for which this small 
number is likely to be sufficient.  The DCE-MRI data were acquired with sufficient temporal 
resolution to support tracer kinetics modelling, but the varying tumour locations made 
measurement of an arterial input function extremely challenging.  We therefore opted to 
use a semi-quantitative parameter instead, but modelling could perhaps have given further 
insight17.  Future work could include modelling, if suitable spatial resolution can be obtained, 
and an MR-linac could allow more detailed monitoring during treatment33. 
 
Commented [KL4]: Added in response to reviewer 2 


































































Overall, this work has resulted in a feasible imaging protocol aligning with domain I of the 
imaging biomarker road map. We identified significant changes in T1 and ADC during 
treatment.  As iAUC relates to hypoxia, an established adverse prognostic factor in STS34, it 
may be suitable as a non-invasive biomarker of tumour microenvironment and should be 
explored in a larger study. 
References 
1.  National Cancer Intelligence Network. Bone and Soft Tissue Sarcomas UK Incidence 
and Survival : 1996 to 2010. Natl Cancer Intellignece Netw. 2013;(November 2013):17. 
http://ncin.org.uk/view?rid=2353. 
2.  Coindre JM, Terrier P, Guillou L, et al. Predictive value of grade for metastasis 
development in the main histologic types of adult soft tissue sarcomas: A study of 
1240 patients from the French Federation of Cancer Centers sarcoma group. Cancer. 
2001;91(10):1914-1926. doi:10.1002/1097-0142(20010515)91:10<1914::AID-
CNCR1214>3.0.CO;2-3 
3.  Roberge D, Skamene T, Nahal A, Turcotte RE, Powell T, Freeman C. Radiological and 
pathological response following pre-operative radiotherapy for soft-tissue sarcoma. 
Radiother Oncol. 2010;97(3):404-407. doi:10.1016/j.radonc.2010.10.007 
4.  Le Grange F, Cassoni AM, Seddon BM. Tumour volume changes following pre-
operative radiotherapy in borderline resectable limb and trunk soft tissue sarcoma. 
Eur J Surg Oncol. 2014;40(4):394-401. doi:10.1016/j.ejso.2014.01.011 
5.  Dangoor A, Seddon B, Gerrand C, Grimer R, Whelan J, Judson I. UK guidelines for 
the management of soft tissue sarcomas. Clin Sarcoma Res. 2016;6(1):20. 
doi:10.1186/s13569-016-0060-4 
6.  DAVIS A, OSULLIVAN B, TURCOTTE R, et al. Late radiation morbidity following 
randomization to preoperative versus postoperative radiotherapy in extremity soft 


































































7.  Eilber FC, Rosen G, Eckardt J, et al. Treatment-Induced Pathologic Necrosis: A 
Predictor of Local Recurrence and Survival in Patients Receiving Neoadjuvant Therapy 
for High-Grade Extremity Soft Tissue Sarcomas. Bönig H, ed. J Clin Oncol. 
2001;19(13):3203-3209. doi:10.1200/JCO.2001.19.13.3203 
8.  Shah D, Borys D, Martinez SR, et al. Complete pathologic response to neoadjuvant 
radiotherapy is predictive of oncological outcome in patients with soft tissue 
sarcoma. Anticancer Res. 2012;32(9):3911-3915. doi:10.1038/mp.2011.182.doi 
9.  MacDermed DM, Miller LL, Peabody TD, et al. Primary Tumor Necrosis Predicts 
Distant Control in Locally Advanced Soft-Tissue Sarcomas After Preoperative 
Concurrent Chemoradiotherapy. Bönig H, ed. Int J Radiat Oncol. 2010;76(4):1147-
1153. doi:10.1016/j.ijrobp.2009.03.015 
10.  Miki Y, Ngan S, Clark JCMCM, Akiyama T, Choong PFMFM. The significance of size 
change of soft tissue sarcoma during preoperative radiotherapy. Eur J Surg Oncol. 
2010;36(7):678-683. doi:10.1016/j.ejso.2010.05.021 
11.  Pasquier D, Hadj Henni A, Escande A, et al. Diffusion weighted MRI as an early 
predictor of tumor response to hypofractionated stereotactic boost for prostate 
cancer. Sci Rep. 2018;8(1):10407. doi:10.1038/s41598-018-28817-9 
12.  Pham TT, Liney GP, Wong K, Barton MB. Functional MRI for quantitative treatment 
response prediction in locally advanced rectal cancer. Br J Radiol. 
2017;90(1072):20151078. doi:10.1259/bjr.20151078 
13.  Suh CH, Kim HS, Jung SC, Choi CG, Kim SJ. Multiparametric MRI as a potential 
surrogate endpoint for decision-making in early treatment response following 
concurrent chemoradiotherapy in patients with newly diagnosed glioblastoma: a 
systematic review and meta-analysis. Eur Radiol. 2018;28(6):2628-2638. 
doi:10.1007/s00330-017-5262-5 
14.  Chung PWM, Deheshi BM, Ferguson PC, et al. Radiosensitivity translates into 


































































soft tissue sarcomas. Cancer. 2009;115(14):3254-3261. doi:10.1002/cncr.24375 
15.  Soldatos T, Ahlawat S, Montgomery E, Chalian M, Jacobs MA, Fayad LM. 
Multiparametric Assessment of Treatment Response in High-Grade Soft-Tissue 
Sarcomas with Anatomic and Functional MR Imaging Sequences. Radiology. 
2016;278(3):831-840. doi:10.1148/radiol.2015142463 
16.  Meyer JM, Perlewitz KS, Hayden JB, et al. Phase I Trial of Preoperative Chemoradiation 
plus Sorafenib for High-Risk Extremity Soft Tissue Sarcomas with Dynamic Contrast-
Enhanced MRI Correlates. Clin Cancer Res. 2013;19(24):6902-6911. doi:10.1158/1078-
0432.CCR-13-1594 
17.  Xia W, Yan Z, Gao X. Volume fractions of DCE-MRI parameter as early predictor of 
histologic response in soft tissue sarcoma: A feasibility study. Eur J Radiol. 
2017;95(July):228-235. doi:10.1016/j.ejrad.2017.08.021 
18.  Schnapauff D, Zeile M, Niederhagen M Ben, et al. Diffusion-weighted echo-planar 
magnetic resonance imaging for the assessment of tumor cellularity in patients with 
soft-tissue sarcomas. J Magn Reson Imaging. 2009;29(6):1355-1359. 
doi:10.1002/jmri.21755 
19.  O’Connor JPB, Aboagye EO, Adams JE, et al. Imaging biomarker roadmap for cancer 
studies. Nat Rev Clin Oncol. 2017;14(3):169-186. doi:10.1038/nrclinonc.2016.162 
20.  Maeda-Otsuka S, Kajihara I, Tasaki Y, et al. Hypoxia accelerates the progression of 
angiosarcoma through the regulation of angiosarcoma cells and tumor 
microenvironment. J Dermatol Sci. 2019. doi:10.1016/j.jdermsci.2019.01.005 
21.  Forker L, Gaunt P, Sioletic S, et al. The hypoxia marker CAIX is prognostic in the UK 
phase III VorteX-Biobank cohort: An important resource for translational research in 
soft tissue sarcoma. Br J Cancer. 2018. doi:10.1038/bjc.2017.430 
22.  Larsson HB, Rosenbaum S, Fritz-Hansen T. Quantification of the effect of water 
exchange in dynamic contrast MRI perfusion measurements in the brain and heart. 



































































23.  Brookes JA, Redpath TW, Gilbert FJ, Murray AD, Staff RT. Accuracy of T1 measurement 
in dynamic contrast-enhanced breast MRI using two- and three-dimensional variable 
flip angle fast low-angle shot. J Magn Reson Imaging. 1999;9(2):163-171. 
http://www.ncbi.nlm.nih.gov/pubmed/10077009. 
24.  Yang L, Forker L, Irlam JJ, Pillay N, Choudhury A, West CML. Validation of a hypoxia 
related gene signature in multiple soft tissue sarcoma cohorts. Oncotarget. 
2018;9(3):3946-3955. doi:10.18632/oncotarget.23280 
25.  Betts GNJ, Eustace A, Patiar S, et al. Prospective technical validation and assessment 
of intra-tumour heterogeneity of a low density array hypoxia gene profile in head 
and neck squamous cell carcinoma. Eur J Cancer. 2013;49(1):156-165. 
doi:10.1016/j.ejca.2012.07.028 
26.  McRobbie DW, Moore EA, Graves MJ, Prince MR. MRI from Picture to Proton. 
Cambridge: CUP; 2003. 
27.  Einarsd�ttir H, Karlsson M, Wejde J, Bauer HCF. Diffusion-weighted MRI of soft tissue 
tumours. Eur Radiol. 2004;14(6):959-963. doi:10.1007/s00330-004-2237-0 
28.  Dudeck O, Zeile M, Pink D, et al. Diffusion-weighted magnetic resonance imaging 
allows monitoring of anticancer treatment effects in patients with soft-tissue 
sarcomas. J Magn Reson Imaging. 2008;27(5):1109-1113. doi:10.1002/jmri.21358 
29.  Jardim-Perassi B V., Huang S, Dominguez-Viqueira W, et al. Multiparametric MRI and 
coregistered histology identify tumor habitats in breast cancer mouse models. Cancer 
Res. 2019;79(15):3952-3964. doi:10.1158/0008-5472.CAN-19-0213 
30.  Surov A, Meyer HJ, Wienke A. Associations between apparent diffusion coefficient 
(ADC) and KI 67 in different tumors: A meta-analysis. part 2: ADCmin. Oncotarget. 
2018;9(9):8675-8680. doi:10.18632/oncotarget.24006 
31.  Hompland T, Ellingsen C, Galappathi K, Rofstad EK. DW-MRI in assessment of the 


































































xenografts. BMC Cancer. 2014;14(1):1-9. doi:10.1186/1471-2407-14-92 
32.  Rasmussen JH, Olin A, Lelkaitis G, et al. Does multiparametric imaging with 18F-FDG-
PET/MRI capture spatial variation in immunohistochemical cancer biomarkers in head 
and neck squamous cell carcinoma? Br J Cancer. 2020;123(1):46-53. 
doi:10.1038/s41416-020-0876-9 
33.  Kerkmeijer LGW, Fuller CD, Verkooijen HM, et al. The MRI-Linear Accelerator 
Consortium: Evidence-Based Clinical Introduction of an Innovation in Radiation 
Oncology Connecting Researchers, Methodology, Data Collection, Quality Assurance, 
and Technical Development. Front Oncol. 2016;6(October):1-6. 
doi:10.3389/fonc.2016.00215 
34.  Nordsmark M, Alsner J, Keller J, et al. Hypoxia in human soft tissue sarcomas: Adverse 













































































Tumour type, grade, 
stage 
Status as of Jan 
2019 






2 56 M Trunk Myxoid liposarcoma 
G3, T2bN0M0 
No disease 





4 27 M Knee Myxoid liposarcoma 
G3, T2bN0M0 
No disease 
5 29 M Lower leg Myxoid chondrosarcoma 
G3, T2bN0M0 
No disease 




7 41 M Lower leg Myxofibrosarcoma 
G3, T2bN0M0 
No disease but 
chronic inflammation 
post-surgery 
8 62 M Forearm Myxofibrosarcoma  
G3, T1bN0M0 
No disease 
9 24 M Knee Synovial sarcoma 
G3, T2bN0M0 
Lung metastasis 
resected June 2018, 
now no disease 
10 67 M Knee Undifferentiated 
pleomorphic sarcoma 
G3, T2bN0M0 
Died (Acute Myeloid 
Leukaemia) Feb 2018 
11 33 M Thigh Myxoid liposarcoma 
G3, T2bN0M0 
Single metastasis in 
spine August 2018 







































































Trial Imaging protocol 
Sequence Purpose 
Flip angle, 















None ETL 13 256 x 256 
x 20 
Limb: 
25 x 25 x 10 
 
Trunk: 









2 AP EPI factor 128,  
B = 0, 50, 100, 
150, 200, 500, 
1000 s/mm2 











64, 142, 292, 
1050, 2550, 
3950 















2 AP Temporal 
resolution 
1.75 s, 150 
dynamics 
 
a In one case, 26 slices were needed to cover the tumour, leading to a dynamic temporal 
resolution of 3.2 s, and TR values for the SRTFE of 73, 145, 306, 1060, 2560, and 3960 ms. 




































































Pearson correlation coefficients for correlations between imaging and histological 
parameters., with p-values calculated from a t-distribution shown in brackets. 
 T1 iAUC ADC Volume 
 Pre-treatment 
CD31 -0.07 (0.83) -0.28 (0.37) -0.16 (0.63) -0.37 (0.23) 
Ki67 -0.50 (0.10) 0.11 (0.74) -0.55 (0.06) -0.29 (0.36) 
HIF 0.08 (0.80) -0.40 (0.19) 0.04 (0.91) -0.10 (0.76) 
Hypoxia score 0.47 (0.12) -0.64 
(0.03)* 
0.63 (0.03)* -0.16 (0.63) 
 Mid-treatment 
CD31 -0.09 (0.78) -0.43 (0.17)  -0.31 (0.32) -0.32 (0.31) 
Ki67 -0.43 (0.16) -0.05 (0.88) -0.66 
(0.02)* 
-0.31 (0.33) 
HIF 0.03 (0.94) -0.44 (0.16) -0.10 (0.75) -0.13 (0.68) 
Hypoxia score 0.24 (0.45) -0.63 
(0.03)* 
0.58 (0.05) -0.14 (0.66) 
 Post-treatment 
CD31 -0.15 (0.63) -0.26 (0.42) -0.29 (0.36) -0.13 (0.69) 
Ki67 -0.57 (0.05) -0.09 (0.78) -0.44 (0.16) -0.04 (0.66) 
HIF -0.27 (0.40) -0.20 (0.53) -0.36 (0.25) -0.29 (0.37) 





































































Blind Title page 
Title: Feasibility of a multiparametric MRI protocol for imaging biomarkers 
associated with neoadjuvant radiotherapy for soft tissue sarcoma 
 






































































Soft tissue sarcoma (STS) is a rare malignancy with a 5 year overall survival rate of 55%.  
Neoadjuvant radiotherapy is commonly used in preparation for surgery, but methods to 
assess early response are lacking despite pathological response at surgery being predictive 
of overall survival, local recurrence and distant metastasis.  Multiparametric MR imaging 
(mpMRI) is used to assess response in a variety of tumours but lacks a robust, standardised 
method.  The overall aim of this study was to develop a feasible imaging protocol to identify 
imaging biomarkers for further investigation. 
Methods 
Fifteen patients with biopsy-confirmed STS suitable for preoperative radiotherapy and 
radical surgery were imaged throughout treatment.  The mpMRI protocol included 
anatomical, diffusion weighted and dynamic contrast-enhanced imaging, giving estimates 
of apparent diffusion coefficient (ADC) and the area under the enhancement curve at 60 s 
(iAUC60).  Histological analysis of resected tumours included detection of CD31, Ki67, HIF 
and calculation of a hypoxia score. 
Results 
There was a significant reduction in T1 at visit 2 and in ADC at visit 3.  Significant 
associations were found between hypoxia and pre-treatment iAUC60, pre-treatment ADC 
and mid-treatment iAUC60. There was also statistically significant association between mid-
treatment ADC and Ki67.   
Conclusions 
This work showed that mpMRI throughout treatment is feasible in patients with STS having 
neoadjuvant radiotherapy.  The relationships between imaging parameters, tissue 
biomarkers and clinical outcomes warrant further investigation. 


































































mpMRI based biomarkers have good correlation with STS tumour biology and are 





































































Soft tissue sarcoma (STS) is a rare and heterogeneous malignancy. There were 3298 new 
diagnoses in the UK in 2010, and the 5-year overall survival rate was 55%1.  Tumour grade 
is prognostic, with 5-year metastasis-free survival rates of 71% and 44% for intermediate 
and high grade tumours respectively2.  Surgery, the main treatment for STS of the limb and 
trunk, involves excising the lesion along with a tumour-free margin of around 1-2 cm, 
subject to anatomical constraints.  In intermediate/high grade tumours or those which 
require extensive surgery, this is often not possible without risk to function.  In these 
situations, radiotherapy is employed either pre- or post-operatively.  Post-operative 
radiotherapy requires a higher dose being delivered to a larger volume but can be reserved 
for situations where an inadequate margin is obtained. Pre-operative radiotherapy may be 
used to shrink a tumour, for some subtypes3 making a tumour more operable4, or to sterilise 
the margins in preparation for excision5.  The use of a lower dose and reduction in the 
irradiated volume for pre-operative compared to post-operative radiotherapy results in 
similar local control, but with a reduction in late toxicity and better function6. There is no 
consensus on the optimal approach for radiotherapy in STS, with a rationale for both pre 
and post-surgical radiotherapy. 
 
There is currently no method to assess early response to pre-operative radiotherapy, despite 
pathological response at surgery being predictive of overall survival, local recurrence7 and 
distant metastasis8,9.  Imaging biomarkers are attractive because they are non-invasive, and 
MR is available in most centres. Volume change in STS during pre-operative radiotherapy 
is minimal despite marked pathological response3, and tumour size changes (RECIST criteria 
and/or three-dimensional tumour volumes) are poor predictors of tumour-free surgical 



































































Multiparametric MR imaging (mpMRI) has been used to demonstrate radiotherapy response 
early in treatment, which might allow prompt progression to definitive treatment in poorly-
responding tumours11–13. Conversely, some STS such as myxoid liposarcoma may respond 
adequately with lower doses of radiotherapy reducing late effects without compromising 
outcome14.  Use of functional measures such as dynamic contrast-enhanced (DCE) MRI 
(measuring tissue microvasculature), and diffusion-weighted imaging (DWI) (measuring 
restriction of water molecule diffusion) has been shown to increase the ability of imaging 
to reflect the amount of tumour necrosis15–18, but protocols varied widely and image analysis 
often required careful selection of tumour subregions.  Delivery of a robust protocol suitable  
for large multicentre studies is challenging.  This study aligns with domain I of the imaging 
biomarker road map19, assessing the feasibility of delivering a robust protocol across 
different anatomical sites, but within a single institute. 
 
The overall aim of this study was to identify imaging parameters suitable for investigation 
as prognostic factors in a larger study.  The specific aims were to (i) develop a well-tolerated 
imaging protocol allowing for repeat scanning, (ii) identify imaging parameters that change 
significantly during radiotherapy, and (iii) determine relationships between imaging 
parameters and histological features in resected tumour tissue.  As part of this exploratory 
assessment, particular attention was focussed on post-surgical hypoxic regions in the 
resected tumour, a parameter known to affect survival20,21. 
Materials and Methods 
Patients 
In this prospective study, fifteen patients with biopsy-confirmed intermediate or high-grade 
STS suitable for preoperative radiotherapy (50 Gy in 25 fractions) and radical surgery were 
recruited.  This study had a favourable ethical opinion (13/NW/0500) and all patients gave 



































































Patients underwent MRI before radiotherapy (within 4 weeks of the start of treatment), in 
week 2 or 3 of radiotherapy, and 2-4 weeks after radiotherapy.  Within one month of the 
post-radiotherapy visit, the tumours were surgically resected.  At surgery, proximal, distal, 
medial, lateral, depth and superficial margins were demarcated.  
Imaging protocol 
Patients were imaged at 1.5 T (Siemens Magnetom Avanto, Siemens Healthineers, Erlangen, 
Germany) using either the peripheral or body matrix coil with the appropriate elements of 
the spine array.  Imaging began with standard clinical sequences (pre-contrast transverse 
and coronal T1w and T2w, post-contrast transverse and coronal T1w with fat saturation, all 
turbo spin-echo) and continued with trial sequences as shown in table 2.  During the 
dynamic sequence, 0.1 ml/kg Gadovist was injected using a power injector at 2 ml/s, 
followed by 20 ml saline at the same rate.   
Image Analysis 
ADC maps were calculated at the time of acquisition.  Images were analysed using Python 
(Version 3.6).  T1 maps were calculated by fitting the saturation recovery turbo FLASH 
equation on a pixel-by-pixel basis22.  The integrated area under the curve in the first 60 
seconds after injection (iAUC60) was calculated on a pixel-by-pixel basis using trapezoidal 
integration, after converting the signal intensity vs time curves to contrast agent 
concentration vs time curves23.  
 
Tumours were outlined on T2w images by BS (confirmed by a consultant radiologist with 
expertise in MRI), and volumes automatically calculated from the known voxel size.  These 
regions of interest (ROIs) were transferred to the dynamic images by nearest-neighbour 
interpolation and to the ADC maps by referring to anatomical landmarks to ensure that the 


































































plane by one pixel to avoid partial volume effects at the region edges.  The median and 
interquartile range over the whole tumour ROI was calculated for ADC, iAUC60 and T1. 
 
Histological Analysis of Resected Tumours 
Immunohistochemistry was performed on 4 µm sections from formalin-fixed paraffin-
embedded (FFPE) tumour resection samples to score hypoxia inducible factor – 1 alpha 
(HIF-1α), carbonic anhydrase IX (CAIX), antigen KI-67 (Ki67) and CD31. HIF-1α, CAIX and 
Ki67 staining was performed using the Bond-Max Automated staining system (Leica 
Biosystems, Milton Keynes, UK). Slides were de-waxed and rehydrated and antigen retrieval 
was carried out at pH 9.0 for 40 min at 100°C. The primary antibodies were HIF-1a (BD 
Biosciences 610959; 1:100 dilution), CAIX (NCL-L-CAIX, Novascastra, Leica Biosystems; 1:100 
dilution), Ki67 (clone MIB-1, Dako M7240; 1:100 dilution), and CD31 (M0823 Dako; 1:50 
dilution). For HIF-1α, Ki67 and CD31 the negative control was mouse IgG1 (Dako X0931) 
and for CAIX was mouse IgG2a (Dako, Ely, UK, X0943). All dilutions were in antibody diluent 
(Leica AR9352) and negative controls were diluted to the same protein concentration as the 
primary.  Slides were stained using a standard BOND processing protocol (available on 
request) and Bond Polymer Refine Detection System (Leica DS9800). Colorectal cancer cell 
line spheroids with a diameter <500 m were used as a positive control for HIF-1α and 
CAIX. A FFPE biopsy of normal human placenta was used as a positive control for CD31. 
 
The percentage of tumour cells per core expressing membranous CAIX was scored by a 
sarcoma pathologist (PS) at ×8 magnification with negative controls available for 
comparison. Other markers were scored using automated image analysis (Definiens tissue 
studio v.4.2; Definiens, Munich, Germany). 
 
The percentage of tumour material was assessed by a sarcoma pathologist (PS) on a 


































































RNA/DNA Purification Plus Kit (Norgen, Thorold, Ontario, Canada) including DNase I 
treatment. The High-Capacity cDNA Reverse Transcription Kit (Life Technologies, Paisley, 
UK) was used to reverse transcribe total RNA.  cDNA was preamplified using a custom pool 
of TaqMan assays (Life Technologies) and TaqMan PreAmp Master Mix (Life Technologies). 
 
Expression of a 24-gene hypoxia signature derived for STS24 and two endogenous control 
genes selected for STS25 was determined using custom 384-well TaqMan array cards (Life 
Technologies) on a QuantStudio 12K Flex Real-Time PCR System (Life Technologies) using 
TaqMan Fast Advanced Master Mix (Life Technologies) according to the manufacturer’s 
guidelines.  The geometric mean of the endogenous control genes was used for 
normalisation.  Hypoxia scores (HS) were calculated as the normalised median expression 
of the 24 hypoxia genes (note that the median is used due to the small sample size in this 
study, rather than the method presented previously24). 
 
Statistical Analysis 
In this small feasibility study, changes in median T1, ADC and iAUC60 between the three 
visits were assessed using a Wilcoxon signed ranks test.  Correlations between imaging and 
histology parameters were assessed by calculating the Pearson correlation coefficient and 
its associated p-value using the t distribution.  Differences in imaging parameters between 
the tumours with and without CAIX staining was assessed using the Mann-Whitney U test.  
No correction was made for multiple comparisons. 
Results 
Patients 
Figure 1 shows a flow diagram for enrolment, imaging and analysis.  Briefly, by the close of 
the study 15 patients were recruited and twelve scanned (nine had three scans, three had 


































































one patient had died from acute myeloid leukaemia and two had developed metastatic 
disease (one patient had a lung metastasis resected and the other developed a solitary 
spinal metastasis).  
 
Image Analysis 
No significant reduction in volume was observed across visits.  The median volumes with 
their interquartile ranges in cm3 were: 29 (22-51) for visit 1, 34 (23-48) for visit 2 and 25 
(10-32) for visit 3.  In comparison with pre-radiotherapy values, there was a significant 
reduction in T1 at visit 2 (p=0.008) (Figure 2) and in ADC at visit 3 (p=0.04), with example 
ADC maps shown in Fig 3 for two patients.  No significant changes in iAUC60 were seen 
over the three visits. 
 
Histological results 
Pearson correlation coefficients between imaging and histological parameters are shown 
with their p-values in Table 3.  Significant correlations were found between hypoxia scores 
and pre-treatment iAUC60 (r = -0.64, p = 0.03), pre-treatment ADC (r = 0.63, p = 0.03) and 
mid-treatment iAUC60 (r = -0.63, p = 0.03). There was also a significant correlation between 
mid-treatment ADC and Ki67 (r = -0.66, p=0.02).  Stratification of patients by CAIX staining 
demonstrated significant differences in T1 (visit 1 p = 0.003, visit 2 p = 0.01, visit 3 p = 
0.03), and iAUC60 at visit 1 (p = 0.03). 
Discussion 
In this work we developed a mpMRI protocol for STS, including established functional and 
structural imaging, that was acceptable for patients and that could be applied several times 
during radiotherapy.  The imaging protocol is deliverable as shown by the good patient 


































































reported the use of mpMRI in STS in neoadjuvant radiotherapy with a time point early in 
treatment.. 
 
We applied the techniques of DCE-MRI, DWI and T1 measurement to explore radiotherapy-
related changes to tumour tissue not reflected by changes in size.  As found in several 
previous publications3,4,10, size change varied between tumours and was not related to any 
histological parameters measured at surgery.  Since conventional RECIST criteria cannot be 
associated with radiotherapy response, a non-invasive imaging biomarker predictive of 
overall survival, local control7 and distant metastasis8,9 is desirable and could be used to 
stratify patients for treatment intensification or de-intensification.  The tissue T1 decreased 
significantly between baseline and mid-treatment but by the end of radiotherapy the main 
variation in T1 was between patients.  T1 changes can reflect a wide range of alterations in 
tissue structure26 resulting in large variations in values between patients, which complicates 
interpretation of tumour revascularisation between baseline and early treatment.  Tumours 
with positive staining for CAIX had a significantly shorter T1 at all three visits, consistent 
with the expected T1 shortening effect of deoxyhaemoglobin.  ADC increased significantly 
between baseline and post-treatment, as shown in previous work27 and is hypothesised to 
reflect decreased cellularity and increased necrosis28.  Pre-treatment ADC values were similar 
to those reported in previous studies27,28 though, as noted by other authors, the range of 
baseline values was large. 
 
There was an inverse correlation between iAUC60 and hypoxia score.  iAUC60 is a semi-
quantitative parameter with no direct physiological interpretation.  A source of the negative 
correlation observed both at baseline and early in treatment could be poor tumour 
perfusion resulting in a lower iAUC60 and the post treatment hypoxia observed.  This is 
consistent with previous work in a mouse xenograft model, which showed reduced AUC in 


































































positive staining for post-treatment CAIX had significantly higher iAUC60, which is not 
consistent with the expected relationship between iAUC60, perfusion and oxygenation.  The 
inverse correlation between mid-treatment ADC and Ki67 at resection suggests that tumours 
with a good initial response to radiotherapy (lower cell density, higher ADC) subsequently 
have less proliferation at resection.  The relationship between ADC and Ki67 has been 
explored previously, and reported in a meta-analysis that confirmed this negative correlation 
in many tumour types30.  Similarly, tumours that show no staining for CAIX at resection 
(normoxic at surgery) have a significantly higher ADC early in treatment (lower cell density).  
In a previous study in melanoma xenografts, ADC was shown to be inversely related to 
hypoxic fraction determined by pimonidazole staining31.  The relationship between CAIX 
and ADC has been explored previously but no relationship was found32, possibly because 
CAIX is a downstream marker of hypoxia which can be regulated by other factors whereas 
pimonidazole represents a more direct measure.  Correlation between pre-treatment ADC 
and hypoxia score is more difficult to interpret as ADC is measured long before the resection 
of the tumour. 
 
This study has several limitations.  The number of patients was small, prohibiting 
examination of differences between responders and non-responders.  The results should be 
interpreted with caution due to sample size and differences in measurement timepoint, but 
the main aim of the study was to develop a suitable imaging protocol for which this small 
number is likely to be sufficient.  The DCE-MRI data were acquired with sufficient temporal 
resolution to support tracer kinetics modelling, but the varying tumour locations made 
measurement of an arterial input function extremely challenging.  We therefore opted to 
use a semi-quantitative parameter instead, but modelling could perhaps have given further 
insight17.  Future work could include modelling, if suitable spatial resolution can be obtained, 



































































Overall, this work has resulted in a feasible imaging protocol aligning with domain I of the 
imaging biomarker road map. We identified significant changes in T1 and ADC during 
treatment.  As iAUC relates to hypoxia, an established adverse prognostic factor in STS34, it 
may be suitable as a non-invasive biomarker of tumour microenvironment and should be 
explored in a larger study. 
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Tumour type, grade, 
stage 
Status as of Jan 
2019 






2 56 M Trunk Myxoid liposarcoma 
G3, T2bN0M0 
No disease 





4 27 M Knee Myxoid liposarcoma 
G3, T2bN0M0 
No disease 
5 29 M Lower leg Myxoid chondrosarcoma 
G3, T2bN0M0 
No disease 




7 41 M Lower leg Myxofibrosarcoma 
G3, T2bN0M0 
No disease but 
chronic inflammation 
post-surgery 
8 62 M Forearm Myxofibrosarcoma  
G3, T1bN0M0 
No disease 
9 24 M Knee Synovial sarcoma 
G3, T2bN0M0 
Lung metastasis 
resected June 2018, 
now no disease 
10 67 M Knee Undifferentiated 
pleomorphic sarcoma 
G3, T2bN0M0 
Died (Acute Myeloid 
Leukaemia) Feb 2018 
11 33 M Thigh Myxoid liposarcoma 
G3, T2bN0M0 
Single metastasis in 
spine August 2018 







































































Trial Imaging protocol 
Sequence Purpose 
Flip angle, 















None ETL 13 256 x 256 
x 20 
Limb: 
25 x 25 x 10 
 
Trunk: 









2 AP EPI factor 128,  
B = 0, 50, 100, 
150, 200, 500, 
1000 s/mm2 











64, 142, 292, 
1050, 2550, 
3950 















2 AP Temporal 
resolution 
1.75 s, 150 
dynamics 
 
a In one case, 26 slices were needed to cover the tumour, leading to a dynamic temporal 
resolution of 3.2 s, and TR values for the SRTFE of 73, 145, 306, 1060, 2560, and 3960 ms. 




































































Pearson correlation coefficients for correlations between imaging and histological 
parameters., with p-values calculated from a t-distribution shown in brackets. 
 T1 iAUC ADC Volume 
 Pre-treatment 
CD31 -0.07 (0.83) -0.28 (0.37) -0.16 (0.63) -0.37 (0.23) 
Ki67 -0.50 (0.10) 0.11 (0.74) -0.55 (0.06) -0.29 (0.36) 
HIF 0.08 (0.80) -0.40 (0.19) 0.04 (0.91) -0.10 (0.76) 
Hypoxia score 0.47 (0.12) -0.64 
(0.03)* 
0.63 (0.03)* -0.16 (0.63) 
 Mid-treatment 
CD31 -0.09 (0.78) -0.43 (0.17)  -0.31 (0.32) -0.32 (0.31) 
Ki67 -0.43 (0.16) -0.05 (0.88) -0.66 
(0.02)* 
-0.31 (0.33) 
HIF 0.03 (0.94) -0.44 (0.16) -0.10 (0.75) -0.13 (0.68) 
Hypoxia score 0.24 (0.45) -0.63 
(0.03)* 
0.58 (0.05) -0.14 (0.66) 
 Post-treatment 
CD31 -0.15 (0.63) -0.26 (0.42) -0.29 (0.36) -0.13 (0.69) 
Ki67 -0.57 (0.05) -0.09 (0.78) -0.44 (0.16) -0.04 (0.66) 
HIF -0.27 (0.40) -0.20 (0.53) -0.36 (0.25) -0.29 (0.37) 









































































































Assessed for eligibility (n = 18) 
Declined to participate (n = 3) 
Recruited (n= 15) 
Surgery  
6-29 days (mean 19 days) after radiotherapy, tumour 
blocks obtained (n = 12) 
Imaging visit 1 (n = 12) 
0-27 days (mean 5 days) before radiotherapy 
MRI  
N= 12 visits 1 and 2, n=9 visits 1, 2, 3 
Tumour blocks 
N = 12 Ki67, HIF 
N = 10 CD31 




Withdrew before any imaging visits (n= 3) 
Did not complete imaging visit 3 (n= 3) 
Visit 3 not as protocol (n= 2) 
Visit 3 scheduled too early due to scanner 
decommissioning (n= 1) 
Enrollment 
Imaging visit 2 (n = 12) 
Radiotherapy day 8-29 (mean day 18) 
Imaging visit 3 (n=9) 
17-34 days (mean 22 days) after radiotherapy 
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